Sophie Neumann-Piperno
Expertise in
18
conditions

Sophie Neumann-Piperno

Paris, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
Paris, FR 

Overview

Sophie Neumann-Piperno practices practicing medicine in Paris, France.

Ms. Neumann-Piperno is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Metastatic Uveal Melanoma, Uveal Melanoma, Adult Soft Tissue Sarcoma, Hysterectomy, and Tissue Biopsy.

She is actively involved in clinical research, co-authoring 193 peer reviewed articles and participating in 11 clinical trials.

Gender

Female

Locations

Paris, 75005, France
Other Locations
Hôpital Cochin Port Royal
Vandoeuvre-les-nancy, France
Lille, France
Montpellier, France
Bordeaux, France
Gustave Roussy
Villejuif, France
Saint Cloud, France
Marseille, France
Lyon, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas
Phase III Trial Investigating the Potential Benefit of Intensified Peri-operative Chemotherapy With in High-risk CINSARC Patients With Resectable Soft-tissue SARComas
Enrollment Status: Recruiting
Publish Date: October 02, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Ifosfamide
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Enrollment Status: Active_not_recruiting
Publish Date: August 18, 2026
Intervention Type: Drug, Other
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor
Enrollment Status: Completed
Publish Date: August 07, 2026
Intervention Type: Drug
Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine
Study Phase: Phase 1/Phase 2
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Enrollment Status: Completed
Publish Date: July 21, 2026
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
Enrollment Status: Completed
Publish Date: April 23, 2026
Intervention Type: Drug
Study Drugs: Cobimetinib, Atezolizumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial
Enrollment Status: Completed
Publish Date: December 10, 2025
Intervention Type: Drug
Study Drugs: MK3475, Pembrolizumab, Endoxan, Cyclophosphamide, G100, Metronomic
Study Phase: Phase 2
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Combination product
Study Drug: Melphalan/Hepatic Device System
Study Phase: Phase 3
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Synovial Sarcoma
Enrollment Status: Terminated
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

193 Total Publications

Safety and outcome of transscleral fine-needle aspiration biopsy in uveal melanoma: 10-year experience in 347 cases.
Safety and outcome of transscleral fine-needle aspiration biopsy in uveal melanoma: 10-year experience in 347 cases.
Journal: Retina (Philadelphia, Pa.)
Published: June 15, 2026

Frequently Asked Questions about Sophie Neumann-Piperno

Is Sophie Neumann-Piperno a top-rated expert for Metastatic Uveal Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Sophie Neumann-Piperno is classified as an Elite expert for Metastatic Uveal Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sophie Neumann-Piperno participate in research or clinical trials?

Yes. Sophie Neumann-Piperno has published 193 articles and abstracts on conditions like Metastatic Uveal Melanoma. You can view a list of Sophie Neumann-Piperno's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Neumann-Piperno's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 23 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile